Stock 4502 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Delayed Japan Exchange
Other stock markets
 10:16:44 2024-05-01 pm EDT 		5-day change 1st Jan Change
4,128 JPY -0.36% Intraday chart for Takeda Pharmaceutical Company Limited +0.15% +1.83%
Apr. 30 Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion RE
Apr. 26 EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
AQ
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
BU
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
AQ
Takeda to Hold Fiscal Year 2023 Earnings Call on May 9
AQ
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
BU
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
BU
Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura
AQ
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
BU
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
BU
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG in Adult Patients with Newly Diagnosed Ph+ ALL
AQ
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
BU
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab, a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
AQ
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
BU
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
BU
Championing Rare Voices on Rare Disease Day
AQ
FDA Approves Takeda's EOHILIA, the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis
AQ
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
BU
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
BU
Takeda Announces FY2023 Q3 Results, On-track towards Full-Year Management Guidance with Strong Momentum in Growth and Launch Products
AQ
Takeda Announces Chief Financial Officer Succession
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited
  5. Press Releases